dextroamphetamine has been researched along with Adverse Drug Event in 9 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate whether the availability of both dextroamphetamine and methylphenidate provides an opportunity to minimize adverse events in a pediatric attention-deficit/hyperactivity disorder (ADHD) stimulant trial." | 2.79 | Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate. ( Aabech, HS; Ramtvedt, BE; Sundet, K, 2014) |
| " Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, physical examinations, and ECG." | 2.76 | Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. ( Childress, AC; Cutler, AJ; Ferreira-Cornwell, MC; Findling, RL; Gasior, M; Hamdani, M; Squires, L, 2011) |
| " Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications." | 2.55 | An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. ( Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017) |
| "The accelerating rotarod test is a preclinical pharmacodynamic test to assess the effect of a treatment on an animal's motor coordination." | 1.36 | A latent pharmacokinetic time profile to model dose-response survival data. ( Adriaan Bouwknecht, J; Bijnens, L; Jacobs, T; Molenberghs, G; Straetemans, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Elliott, J | 1 |
| Johnston, A | 1 |
| Husereau, D | 1 |
| Kelly, SE | 1 |
| Eagles, C | 1 |
| Charach, A | 1 |
| Hsieh, SC | 1 |
| Bai, Z | 1 |
| Hossain, A | 1 |
| Skidmore, B | 1 |
| Tsakonas, E | 1 |
| Chojecki, D | 1 |
| Mamdani, M | 1 |
| Wells, GA | 1 |
| Ramtvedt, BE | 1 |
| Aabech, HS | 1 |
| Sundet, K | 1 |
| Li, Y | 1 |
| Gao, J | 1 |
| He, S | 1 |
| Zhang, Y | 1 |
| Wang, Q | 1 |
| Jacobs, T | 1 |
| Straetemans, R | 1 |
| Molenberghs, G | 1 |
| Adriaan Bouwknecht, J | 1 |
| Bijnens, L | 1 |
| Findling, RL | 1 |
| Childress, AC | 1 |
| Cutler, AJ | 1 |
| Gasior, M | 1 |
| Hamdani, M | 1 |
| Ferreira-Cornwell, MC | 1 |
| Squires, L | 1 |
| KEITER, WE | 1 |
| ARNOLD, JH | 1 |
| Mukherjee, DK | 1 |
| Mukherjee, K | 1 |
| Springer, NS | 1 |
| Fricke, NL | 1 |
| Annau, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD[NCT01220440] | Phase 4 | 36 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00735371] | Phase 3 | 314 participants (Actual) | Interventional | 2008-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00735371)
Timeframe: Baseline and 1, 2, 3 and 4 weeks
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) 30 mg | -18.3 |
| LDX 50 mg | -21.1 |
| LDX 70 mg | -20.7 |
| Placebo | -12.8 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00735371)
Timeframe: 1, 2, 3 and 4 Weeks
| Intervention | Participants (Number) |
|---|---|
| Lisdexamfetamine Dimesylate (LDX) 30 mg | 44 |
| LDX 50 mg | 53 |
| LDX 70 mg | 57 |
| Placebo | 30 |
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life. (NCT00735371)
Timeframe: Baseline and 4 weeks
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 4 Weeks | |
| LDX 50 mg | 80.5 | 81.3 |
| LDX 70 mg | 78.8 | 81.3 |
| Lisdexamfetamine Dimesylate (LDX) 30 mg | 79.3 | 81.1 |
| Placebo | 79.2 | 81.3 |
3 reviews available for dextroamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes | 2020 |
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidi | 2017 |
Nutrition and drug therapy for persons with developmental disabilities.
Topics: Anticonvulsants; Antidepressive Agents; Appetite; Dextroamphetamine; Drug-Related Side Effects and A | 1975 |
2 trials available for dextroamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dextroamphetam | 2014 |
Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextro | 2011 |
4 other studies available for dextroamphetamine and Adverse Drug Event
| Article | Year |
|---|---|
A latent pharmacokinetic time profile to model dose-response survival data.
Topics: Algorithms; Animals; Computer Simulation; Dextroamphetamine; Dose-Response Relationship, Drug; Drug- | 2010 |
Acute dexedrine intoxication in children.
Topics: Amphetamine; Central Nervous System Agents; Child; Dextroamphetamine; Drug-Related Side Effects and | 1955 |
Ototoxicity of commonly used pharmaceutical preparations.
Topics: Adolescent; Adult; Ampicillin; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Child; Chlor | 1979 |
The use of pharmacological challenges in behavioral toxicology.
Topics: Animals; Behavior, Animal; Dextroamphetamine; Dose-Response Relationship, Drug; Drug-Related Side Ef | 1987 |